100 related articles for article (PubMed ID: 30126000)
1. Identification of pathway-based recurrence-associated signatures in optimally debulked patients with serous ovarian cancer.
Deng K; Zhang F; Song W; Zhao W; Rong Z; Cai Y; Xu H; Lu M; Wang W; Li A; Hou Y; Li Z; Li K
J Cell Biochem; 2018 Nov; 119(10):8564-8573. PubMed ID: 30126000
[TBL] [Abstract][Full Text] [Related]
2. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.
Zhao H; Guo E; Hu T; Sun Q; Wu J; Lin X; Luo D; Sun C; Wang C; Zhou B; Li N; Xia M; Lu H; Meng L; Xu X; Hu J; Ma D; Chen G; Zhu T
Oncotarget; 2016 Jul; 7(28):43924-43938. PubMed ID: 27270322
[TBL] [Abstract][Full Text] [Related]
3. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
4. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.
Zhang W; Ota T; Shridhar V; Chien J; Wu B; Kuang R
PLoS Comput Biol; 2013; 9(3):e1002975. PubMed ID: 23555212
[TBL] [Abstract][Full Text] [Related]
5. MMP-16 as a New Biomarker for Predicting Prognosis and Chemosensitivity of Serous Ovarian Cancer: A Study Based on Bioinformatics Analysis.
Wang W; Liu Y; Yang Y; Huang X; Hou Y
Crit Rev Eukaryot Gene Expr; 2021; 31(4):1-8. PubMed ID: 34587431
[TBL] [Abstract][Full Text] [Related]
6. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
He J; Liu Y; Zhang L; Zhang H
Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
[TBL] [Abstract][Full Text] [Related]
7. Predicting time to ovarian carcinoma recurrence using protein markers.
Yang JY; Yoshihara K; Tanaka K; Hatae M; Masuzaki H; Itamochi H; ; Takano M; Ushijima K; Tanyi JL; Coukos G; Lu Y; Mills GB; Verhaak RG
J Clin Invest; 2013 Sep; 123(9):3740-50. PubMed ID: 23945238
[TBL] [Abstract][Full Text] [Related]
8. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
11. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
Le Page C; Rahimi K; Köbel M; Tonin PN; Meunier L; Portelance L; Bernard M; Nelson BH; Bernardini MQ; Bartlett JMS; Bachvarov D; Gotlieb WH; Gilks B; McAlpine JN; Nachtigal MW; Piché A; Watson PH; Vanderhyden B; Huntsman DG; Provencher DM; Mes-Masson AM
BMC Cancer; 2018 Mar; 18(1):347. PubMed ID: 29587661
[TBL] [Abstract][Full Text] [Related]
13. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
[TBL] [Abstract][Full Text] [Related]
14. Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.
Yang X; Zheng M; Ning Y; Sun J; Yu Y; Zhang S
J Transl Med; 2023 Jul; 21(1):456. PubMed ID: 37434173
[TBL] [Abstract][Full Text] [Related]
15. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.
Zhang F; Zhang Y; Ke C; Li A; Wang W; Yang K; Liu H; Xie H; Deng K; Zhao W; Yang C; Lou G; Hou Y; Li K
Metabolomics; 2018 Apr; 14(5):65. PubMed ID: 30830339
[TBL] [Abstract][Full Text] [Related]
16. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
17. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Høgdall E
PLoS One; 2018; 13(11):e0207319. PubMed ID: 30475821
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
[TBL] [Abstract][Full Text] [Related]
20. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
